Merck & Co., Inc. (MRK)

81.94
0.49 0.60
NYSE
Prev Close 81.45
Open 81.14
Day Low/High 81.11 / 81.96
52 Wk Low/High 65.25 / 92.64
Volume 8.21M
Exchange NYSE
Shares Outstanding 2530.03B
Market Cap 207.03B
P/E Ratio 17.98
Div & Yield N.A. (N.A)
6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Take the Billionaire Investors With a Grain of Salt

Jim Cramer: Take the Billionaire Investors With a Grain of Salt

Despite the rhetoric from on high, it is possible to find good stock picks in this market.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Merck's Decline Today Looks Like an Opportunity to Buy the Dip

Merck's Decline Today Looks Like an Opportunity to Buy the Dip

Let's visit with the charts of MRK.

Jim Cramer: Lack of Individual Stock Pickers Has Led to This Equity Glut

Jim Cramer: Lack of Individual Stock Pickers Has Led to This Equity Glut

We don't have enough stock pickers or individuals to handle all the new stock that's been created. And It is trashing the cloud kings, among others.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Jim Cramer: The Market Is Lapping Up These Stocks

Jim Cramer: The Market Is Lapping Up These Stocks

There are plenty of senior growth companies that can still move higher.

Jim Cramer: What Would Make a Good Stock in This Environment?

Jim Cramer: What Would Make a Good Stock in This Environment?

Let me give you the items I want to see before I bless buying anything in what has become a plain, out and out, treacherous market.

Buying Merck? Here's the One Technical Level to Watch

Buying Merck? Here's the One Technical Level to Watch

The longer-term picture of MRK is positive.

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.

Merck Shares Could Trade Sideways Before Renewed Gains

Merck Shares Could Trade Sideways Before Renewed Gains

Let's visit with the charts and indicators to get another perspective.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

U.S./China Talks, Gold and Copper, Mastercard Poised for Breakout: Market Recon

U.S./China Talks, Gold and Copper, Mastercard Poised for Breakout: Market Recon

In my opinion, MA is a good one, otherwise it would not be on my book.

A Rough September Ahead, Staying Nimble, 3 Breakout Stocks: Market Recon

A Rough September Ahead, Staying Nimble, 3 Breakout Stocks: Market Recon

These three names - GD, MRK, WMT - will either hit resistance or hurdle immediate pivot points in as traders (or bots) try to form a technical breakout.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

A Bottoms Up Look at the Dow Industrials

A Bottoms Up Look at the Dow Industrials

Stock by stock checking on how many were in uptrends.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

Merck Could Push Higher in the Weeks and Months Ahead - $100 Is in the Cards

Merck Could Push Higher in the Weeks and Months Ahead - $100 Is in the Cards

Here's an updated strategy.

Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now

Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now

I am neutral on this market, and only a cool off of the hottest stocks can justify a further advance.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Merck & Co. Rated New Buy at Mizuo

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Here's Why I'm Sticking With Merck

Here's Why I'm Sticking With Merck

The charts are saying MRK is ready to rise.